- In April 2024, the U.S. FDA approved ZEVTERA (ceftobiprole), marking the first MRSA-active cephalosporin available since 2006. It's authorized for treating bloodstream infections (including right-sided endocarditis), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired pneumonia for patients aged 3 months and older
- In February 2024, the fixed-dose combination Exblifep (cefepime/enmetazobactam) was approved in both the U.S. and EU for treating complicated urinary tract infections. This represents a significant step forward in combating ESBL-producing gram-negative pathogens
- In November 2023, Japan’s Ministry of Health approved Fetroja (cefiderocol) for treating carbapenem-resistant infections (Such as, E. coli, Klebsiella, Pseudomonas) and introduced drug‑susceptibility testing protocols alongside its launch
- In October 2021, Sandoz, a division of Novartis, successfully completed its acquisition of GSK’s cephalosporin antibiotics business. As part of the deal, Sandoz gained the rights to three well-established brands—Zinnat, Zinacef, and Fortum—across more than 100 markets, strengthening its global leadership in the antibiotics sector
